| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/02/2002 | EP1200133A1 Manipulation of tissue or organ type using the notch pathway |
| 05/02/2002 | EP1200130A2 Methods for treating therapy-resistant tumors |
| 05/02/2002 | EP1200128A1 Preserved pharmaceutical formulations |
| 05/02/2002 | EP1200127A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 05/02/2002 | EP1200123A1 Diagnosis and treatment of neuroectodermal tumors |
| 05/02/2002 | EP1200114A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 05/02/2002 | EP1200112A2 Chemokine binding protein of gammaherpesvirus 68 and methods of use therefor |
| 05/02/2002 | EP1200110A1 In vivo induction for enhanced function of isolated hepatocytes |
| 05/02/2002 | EP1200102A1 Methods for treating autoimmune diseases |
| 05/02/2002 | EP1200101A1 Methods for transdifferentiation of body tissues |
| 05/02/2002 | EP1200099A1 Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds |
| 05/02/2002 | EP1200095A1 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances |
| 05/02/2002 | EP1200094A1 Ophthalmic compositions containing antibiotics and nsaids |
| 05/02/2002 | EP1200086A2 Methods for treating or preventing pain and anxiety |
| 05/02/2002 | EP1200084A1 Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications |
| 05/02/2002 | EP1200082A1 Preparations for reducing oxygen consumption during physical efforts |
| 05/02/2002 | EP1200080A1 Assay for d-serine transport antagonist and use for treating psychosis |
| 05/02/2002 | EP1200078A1 Compositions and methods for promoting nerve regeneration |
| 05/02/2002 | EP1200076A1 Calcilytic compounds |
| 05/02/2002 | EP1200074A2 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 05/02/2002 | EP1200073A2 SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 05/02/2002 | EP1200072A2 Method of treating psychotic disorders |
| 05/02/2002 | EP1200040A1 Two-component composition for cosmetic or pharmaceutical use |
| 05/02/2002 | EP1200039A2 Emulsifier-free finely dispersed water-in-oil-type systems |
| 05/02/2002 | EP1173192A4 Methods and compositions for targeted drug delivery |
| 05/02/2002 | EP0928192B1 Antimycotic gel with high active substance release |
| 05/02/2002 | EP0879056B1 Modulation of th1/th2 cytokine expression by ribavirin in activated t-lymphocytes |
| 05/02/2002 | EP0847279B1 Antipruriginous cosmetic and/or pharmaceutical compositions consisting of one or several light local anaesthetics and one or several astringent substances |
| 05/02/2002 | EP0841907B1 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity |
| 05/02/2002 | EP0814784B1 USE OF NSAIDs FOR TREATMENT OF SQUAMOUS CELL CARCINOMAS OF THE ORAL CAVITY OR OROPHARYNX |
| 05/02/2002 | EP0772442B1 Use of immunosuppressive agents for the treatment of schizophrenia |
| 05/02/2002 | EP0746567B1 Novel opioid peptides for the treatment of pain and use thereof |
| 05/02/2002 | DE10053397A1 Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen Use of a dopaminergic agent for the treatment of dopaminergic treatable diseases |
| 05/02/2002 | DE10049549A1 Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40 |
| 05/02/2002 | CA2689012A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2678256A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2464228A1 Vaccine immunotherapy for immune suppressed patients |
| 05/02/2002 | CA2457111A1 Vaccine for treating allergy |
| 05/02/2002 | CA2428907A1 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy |
| 05/02/2002 | CA2427085A1 Transmembrane proteins |
| 05/02/2002 | CA2427024A1 Methods for screening compounds that modulate lipid metabolism |
| 05/02/2002 | CA2426902A1 Methods of improving central nervous system functioning |
| 05/02/2002 | CA2426896A1 Compositions and methods for the discovery and selection of biological information |
| 05/02/2002 | CA2426779A1 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors |
| 05/02/2002 | CA2426773A1 Beta-substituted beta-aminoethyl phosphonates |
| 05/02/2002 | CA2426767A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 05/02/2002 | CA2426672A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 05/02/2002 | CA2426465A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 05/02/2002 | CA2426294A1 Nucleic acid generating the abca7 gene, molecules modulating its activity and therapeutic applications |
| 05/02/2002 | CA2425897A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 05/02/2002 | CA2425596A1 Methods of therapy for hiv infection |
| 05/02/2002 | CA2424475A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2421885A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2420164A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/01/2002 | CN1347420A Growth hormone secretagogues |
| 05/01/2002 | CN1347327A Methods for glucagon suppression |
| 05/01/2002 | CN1347326A BAFF, inhibitors thereof and their use in modulation of B-cell response |
| 05/01/2002 | CN1347321A Use of vasopeptidase inhibitors to treat angina pectoris |
| 05/01/2002 | CN1347318A Inhibitors of IMPDH enzyme |
| 05/01/2002 | CN1347310A Skin care compositions contg. combination of skin care actives |
| 05/01/2002 | CN1083717C Extract from leaves of gingko biloba |
| 05/01/2002 | CN1083715C Use of insulin sensitisers for treating renal diseases |
| 04/30/2002 | US6380405 Taxane prodrugs |
| 04/30/2002 | US6380374 Isolated nucleic acid; culture product |
| 04/30/2002 | US6380363 Antibodies to the Ob receptor |
| 04/30/2002 | US6380261 Administering to retina antagonist of the nmda receptor-channel complex for therapy of proliferative vitreoretinopathy resulting from penetrating trauma, retinal tear, traction detachment, vitrectomy or intraocular surgery |
| 04/30/2002 | US6380258 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 04/30/2002 | US6380255 Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds |
| 04/30/2002 | US6380253 Obtaining initial radiographic image of a region containing glioma; injecting into glioma region an anti-angiogenic substance which is linked to sodium salt solution of polyunsaturated fatty acid; obtaining image; evaluation |
| 04/30/2002 | US6380236 Method of treating onychomycosis |
| 04/30/2002 | US6380228 E.g., n-(2-phenylsulfonyl-1-ethyl)-3-(4-cyanophenyl)-2,3-dihydro-imidazo(2,1 -b)thiazole-5-carboxamide hydrochloride; treating cancer, neurofibromin benign proliferative disorder, retinal vascularization, and hepatitis delta |
| 04/30/2002 | US6380218 For therapy of respiratory, allergic, and inflammatory disorders comprising asthma, chronic obstructive pulmonary disease, acute respiratory disease syndrome, pulmonary hypersensitivity, and allergic rhinitis in a mammal |
| 04/30/2002 | US6380200 Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications |
| 04/30/2002 | US6380199 Treatment of attention deficit hyperactivity disorder |
| 04/30/2002 | US6380183 Treatment of diseases involving cyst formation |
| 04/30/2002 | US6380178 Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
| 04/30/2002 | US6380155 Use of vasopressin receptor antagonist for regulation of ACTH release |
| 04/30/2002 | US6379950 Recombinant, active caspases and uses thereof |
| 04/30/2002 | US6379945 Gene switch |
| 04/30/2002 | US6379913 A polypeptide encoding an amino acid sequence; prevention and therapy for diabetes, inflammatory glomerulonephritis, ischemis renal failure, artherosclerosis, coronary vasoconstriction and ischemic heart disease |
| 04/30/2002 | US6379710 Membranes; three-dimensional shapes |
| 04/30/2002 | US6379706 Rapidly disintegrating coated pellets with delayed release |
| 04/30/2002 | US6379702 Flexibility; contour conforming; applying to skins |
| 04/30/2002 | US6379699 Liposome having attached target-binding moiety and artherosclerotic plaque interacting moiety |
| 04/30/2002 | US6379696 Adjust absorption |
| 04/30/2002 | US6379667 Medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction |
| 04/30/2002 | US6379662 Human interleukin variation |
| 04/30/2002 | US6379651 Administering and ingesting peroral tablets of an antibiotic/antibacterial compound with a bismuth compound, and chewing within oral cavity |
| 04/30/2002 | CA2360049A1 Assays for identifying phosphatase inhibitors |
| 04/30/2002 | CA2358678A1 Heterocyclic derivatives useful as pharmaceutical agents |
| 04/30/2002 | CA2267503C Methods and compositions for preventing and treating heartburn |
| 04/30/2002 | CA2059319C Formulations for oral administration, in particular to ruminants |
| 04/30/2002 | CA2042937C Treatment of ocular hypertension with a synergistic combination |
| 04/30/2002 | CA2042936C Treatment of ocular hypertension with a synergistic combination for ophthalmic use |
| 04/30/2002 | CA2020247C Antibodies reactive with human carcinomas |
| 04/26/2002 | CA2359877A1 Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| 04/25/2002 | WO2002033100A2 Regulation of human adenylate cyclase, type iv |
| 04/25/2002 | WO2002033099A2 Human kinases |
| 04/25/2002 | WO2002033095A2 Regulation of human serine-threonine protein kinase |
| 04/25/2002 | WO2002033086A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |